Substance / Medication

Omeprazole magnesium

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Esophagitis

Duodenal ulcer disease

Zollinger-Ellison syndrome

Gastroesophageal reflux disease

Gastric ulcer

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Pharmacokinetics of Esomeprazole Magnesium After Single Oral Doses in Healthy Subjects: Bioequivalence Study and Food Effects.

Zhong Xue-Feng, Zhou Gan, Xu Su-Mei et al. · Clin Pharmacol Drug Dev · 2022

PMID: 35822412RCT

[Evaluation of drug-drug interactions between yimitasvir phosphate capsules with sofosbuvir tablets, omeprazole magnesium enteric-coated tablets, and rosuvastatin calcium tablets].

Mai J J, Zhang H, Peng Y Y et al. · Zhonghua Gan Zang Bing Za Zhi · 2020

PMID: 33105928RCT

Comparison of esomeprazole enteric-coated capsules vs esomeprazole magnesium in the treatment of active duodenal ulcer: a randomized, double-blind, controlled study.

Liang Xiao-Yan, Gao Qing, Gong Neng-Ping et al. · World J Gastroenterol · 2008

PMID: 18350637RCTFull text (PMC)

Preparation and characterization of pH-sensitive methyl methacrylate-g-starch/hydroxypropylated starch hydrogels: in vitro and in vivo study on release of esomeprazole magnesium.

Kumar Pankaj, Ganure Ashok Laxmanrao, Subudhi Bharat Bhushan et al. · Drug Deliv Transl Res · 2015

PMID: 25787732Observational

Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.

Choi YoonJung, Han HyeKyung, Shin Dongseong et al. · Drug Des Devel Ther · 2015

PMID: 26257511ObservationalFull text (PMC)

A comparative study of the novel spectrophotometric methods versus conventional ones for the simultaneous determination of Esomeprazole magnesium trihydrate and Naproxen in their binary mixture.

Lotfy Hayam M, Amer Sawsan M, Zaazaa Hala E et al. · Spectrochim Acta A Mol Biomol Spectrosc · 2015

PMID: 26162342Observational

A validated stability indicating ultra performance liquid chromatographic method for determination of impurities in Esomeprazole magnesium gastro resistant tablets.

Nalwade Santaji Uttam, Reddy Vangala Ranga, Rao Dantu Durga et al. · J Pharm Biomed Anal · 2012

PMID: 21920688Observational

Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium.

Wang-Smith Laurene, Fort John, Zhang Ying et al. · J Clin Pharmacol · 2012

PMID: 21628602Observational

Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone.

Goldstein J L, Hochberg M C, Fort J G et al. · Aliment Pharmacol Ther · 2010

PMID: 20497139Observational

Direct HPLC enantioseparation of omeprazole and its chiral impurities: application to the determination of enantiomeric purity of esomeprazole magnesium trihydrate.

Zanitti Leo, Ferretti Rosella, Gallinella Bruno et al. · J Pharm Biomed Anal · 2010

PMID: 20338705Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Omeprazole magnesium (substance)
SNOMED CT: 384973006
UMLS CUI: C0771765

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.